Rasch-built Overall Disability Scale (R-ODS) for immune-mediated peripheral neuropathies
- PMID: 21263135
- DOI: 10.1212/WNL.0b013e318208824b
Rasch-built Overall Disability Scale (R-ODS) for immune-mediated peripheral neuropathies
Abstract
Objective: To develop a patient-based, linearly weighted scale that captures activity and social participation limitations in patients with Guillain-Barré syndrome (GBS), chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), and gammopathy-related polyneuropathy (MGUSP).
Methods: A preliminary Rasch-built Overall Disability Scale (R-ODS) containing 146 activity and participation items was constructed, based on the WHO International Classification of Functioning, Disability and Health, literature search, and patient interviews. The preliminary R-ODS was assessed twice (interval: 2-4 weeks; test-retest reliability studies) in 294 patients who experienced GBS in the past (n = 174) or currently have stable CIDP (n = 80) or MGUSP (n = 40). Data were analyzed using the Rasch unidimensional measurement model (RUMM2020).
Results: The preliminary R-ODS did not meet the Rasch model expectations. Based on disordered thresholds, misfit statistics, item bias, and local dependency, items were systematically removed to improve the model fit, regularly controlling the class intervals and model statistics. Finally, we succeeded in constructing a 24-item scale that fulfilled all Rasch requirements. "Reading a newspaper/book" and "eating" were the 2 easiest items; "standing for hours" and "running" were the most difficult ones. Good validity and reliability were obtained.
Conclusion: The R-ODS is a linearly weighted scale that specifically captures activity and social participation limitations in patients with GBS, CIDP, and MGUSP. Compared to the Overall Disability Sum Score, the R-ODS represents a wider range of item difficulties, thereby better targeting patients with different ability levels. If responsive, the R-ODS will be valuable for future clinical trials and follow-up studies in these conditions.
Similar articles
-
Improving fatigue assessment in immune-mediated neuropathies: the modified Rasch-built fatigue severity scale.J Peripher Nerv Syst. 2009 Dec;14(4):268-78. doi: 10.1111/j.1529-8027.2009.00238.x. J Peripher Nerv Syst. 2009. PMID: 20021568
-
Correlation of the patient's reported outcome Inflammatory-RODS with an objective metric in immune-mediated neuropathies.Eur J Neurol. 2016 Jul;23(7):1248-53. doi: 10.1111/ene.13025. Epub 2016 Apr 29. Eur J Neurol. 2016. PMID: 27129110
-
Distinguishing acute-onset CIDP from fluctuating Guillain-Barre syndrome: a prospective study.Neurology. 2010 May 25;74(21):1680-6. doi: 10.1212/WNL.0b013e3181e07d14. Epub 2010 Apr 28. Neurology. 2010. PMID: 20427754
-
[Inflammatory polyneuropathies can be treated successfully].Lakartidningen. 2012 May 9-15;109(19):950-4. Lakartidningen. 2012. PMID: 22734259 Review. Swedish. No abstract available.
-
Guillain Barré syndrome and other immune mediated neuropathies: diagnosis and classification.Autoimmun Rev. 2014 Apr-May;13(4-5):525-30. doi: 10.1016/j.autrev.2014.01.033. Epub 2014 Jan 13. Autoimmun Rev. 2014. PMID: 24434363 Review.
Cited by
-
Long-term safety and efficacy of subcutaneous immunoglobulin IgPro20 in CIDP: PATH extension study.Neurol Neuroimmunol Neuroinflamm. 2019 Jul 3;6(5):e590. doi: 10.1212/NXI.0000000000000590. eCollection 2019 Sep. Neurol Neuroimmunol Neuroinflamm. 2019. PMID: 31355323 Free PMC article. Clinical Trial.
-
Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy.J Neurol. 2021 Jun;268(6):2109-2122. doi: 10.1007/s00415-019-09688-0. Epub 2020 Jan 6. J Neurol. 2021. PMID: 31907599 Free PMC article. Review.
-
Theory of mind and executive dysfunction in chronic inflammatory demyelinating polyneuropathy.Eur J Neurol. 2024 Jan;31(1):e16053. doi: 10.1111/ene.16053. Epub 2023 Sep 9. Eur J Neurol. 2024. PMID: 37688443 Free PMC article.
-
Use of Magnetic Resonance Neurography for Evaluating the Distribution and Patterns of Chronic Inflammatory Demyelinating Polyneuropathy.Korean J Radiol. 2020 Apr;21(4):483-493. doi: 10.3348/kjr.2019.0739. Korean J Radiol. 2020. PMID: 32193896 Free PMC article.
-
Trial design and rationale for APOLLO, a Phase 3, placebo-controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy.BMC Neurol. 2017 Sep 11;17(1):181. doi: 10.1186/s12883-017-0948-5. BMC Neurol. 2017. PMID: 28893208 Free PMC article. Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous